|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 74.97 USD | +0.15% |
|
+0.23% | +4.00% |
| 12-02 | Hologic, Inc. and Biotheranostics, Inc. Announces 11 Studies Featuring the Breast Cancer Index®? Test | CI |
| 11-25 | Hologic, Inc. to Showcase its Latest Innovations at RSNA | CI |
| Capitalization | 16.69B 14.34B 13.43B 12.52B 23.05B 1,500B 25.14B 157B 60.61B 710B 62.62B 61.28B 2,591B | P/E ratio 2026 * |
21.5x | P/E ratio 2027 * | 18.7x |
|---|---|---|---|---|---|
| Enterprise value | 16.26B 13.97B 13.09B 12.2B 22.46B 1,462B 24.5B 153B 59.08B 692B 61.03B 59.73B 2,526B | EV / Sales 2026 * |
3.79x | EV / Sales 2027 * | 3.42x |
| Free-Float |
74.01% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Hologic, Inc.
| 1 day | +0.15% | ||
| 1 week | +0.23% | ||
| 1 month | +1.16% | ||
| 3 months | +12.92% | ||
| 6 months | +19.82% | ||
| Current year | +4.00% |
| 1 week | 74.55 |  | 75.12 |
| 1 month | 74.07 | | 75.12 |
| Current year | 51.9 | | 75.12 |
| 1 year | 51.9 | | 80.31 |
| 3 years | 51.9 | | 87.88 |
| 5 years | 51.9 | | 87.88 |
| 10 years | 26.49 | | 87.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 06/12/2013 | |
Karleen Oberton
DFI | Director of Finance/CFO | 55 | 31/07/2018 |
Essex Mitchell
COO | Chief Operating Officer | 45 | 31/12/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 31/10/2011 | |
| Chairman | 61 | 15/06/2015 | |
| Director/Board Member | 70 | 14/05/2017 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 2.06% | 5 M€ | 0.00% | - |
| 1.98% | 2 M€ | -.--% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.15% | +0.23% | -2.47% | -2.00% | 16.69B | |
| -0.43% | -3.45% | +8.30% | +1.74% | 216B | |
| +1.18% | +0.19% | +4.62% | +111.33% | 202B | |
| -0.39% | -0.97% | -4.24% | -17.50% | 160B | |
| -0.20% | -3.41% | +7.35% | +109.27% | 145B | |
| +1.92% | +1.80% | -15.94% | -15.65% | 55.5B | |
| +0.48% | -0.65% | +16.16% | +12.59% | 49.78B | |
| -1.91% | -5.75% | +3.77% | -6.54% | 41.98B | |
| +3.56% | +5.99% | +2.95% | - | 37.59B | |
| +2.00% | +0.59% | +4.36% | +10.15% | 36.66B | |
| Average | +0.16% | -1.19% | +2.49% | +22.60% | 96.12B | |
| Weighted average by Cap. | +0.04% | -1.67% | +3.56% | +38.61% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.29B 3.68B 3.45B 3.22B 5.92B 385B 6.46B 40.27B 15.57B 182B 16.09B 15.74B 666B | 4.51B 3.88B 3.63B 3.39B 6.23B 406B 6.8B 42.38B 16.39B 192B 16.93B 16.57B 701B |
| Net income | 776M 667M 625M 582M 1.07B 69.8B 1.17B 7.29B 2.82B 33.01B 2.91B 2.85B 121B | 889M 763M 715M 667M 1.23B 79.88B 1.34B 8.35B 3.23B 37.78B 3.33B 3.26B 138B |
| Net Debt | -423M -364M -340M -317M -584M -38.04B -638M -3.97B -1.54B -17.99B -1.59B -1.55B -65.71B | -1.24B -1.06B -995M -928M -1.71B -111B -1.86B -11.62B -4.49B -52.6B -4.64B -4.54B -192B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/25 | 74.97 $ | +0.15% | 1,725,558 |
| 04/12/25 | 74.86 $ | -0.20% | 3,630,450 |
| 03/12/25 | 75.01 $ | +0.25% | 1,263,313 |
| 02/12/25 | 74.82 $ | -0.03% | 1,984,956 |
| 01/12/25 | 74.84 $ | -0.17% | 2,002,615 |
Delayed Quote Nasdaq, December 05, 2025 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HOLX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition